No Data
No Data
Leerink Partners Maintains Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $20
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Solid Biosciences (SLDB) and Moderna (MRNA)
Express News | Solid Biosciences Inc : Leerink Partners Cuts Target Price to $20 From $28
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Promising Potential of Solid Biosciences' SGT-003 Therapy Drives Buy Rating
Insider Purchase: 10% Owner at $SLDB Buys 1,000,000 Shares